MetaCap

Dare Bioscience (DARE) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dare Bioscience (DARE) has outperformed Palatin Technologies (PTN) over the past year, losing 75.8% versus a loss of 79.9%. Over five years, DARE leads with a -98.1% price change compared with -99.3% for PTN. Palatin Technologies is the larger company by market cap ($8.2 million vs $8.0 million), about 1.0 times the size.

Palatin Technologies converts more of its revenue into profit, with a net margin of -94.9% versus -1300.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DARE-75.75%PTN-79.93%
+103%+7%-89%
Nov 21, 20251 yearNov 20, 2026
DARE-97.97%PTN-98.98%
+69%-19%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DARE versus PTN key metrics
MetricDAREPTN
Share price$0.4074$4.58
Market cap$8.01M$8.16M
1-day change-9.87%-7.10%
YTD return-78.89%-70.22%
1-year return-75.75%-79.93%
5-year return-98.10%-99.35%
EPS (TTM)$-0.61$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.03M$8.83M
Revenue growth (YoY)+10429.36%—
Net income (latest FY)$-13.40M$-8.38M
Gross margin71.29%—
Operating margin-1315.51%-98.17%
Net margin-1300.66%-94.88%
52-week high$3.78$31.00
52-week low$0.406$4.51
Distance from 52-week high-89.22%-85.23%
Analyst consensusnonestrong_buy
Avg. price target upside+1944.67%+1068.12%
Average volume242.39K71.93K
Shares outstanding19.67M1.78M
Employees2125
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Palatin Technologies is more profitable, keeping -94.9 cents of every revenue dollar as net income versus -1300.7 cents for Dare Bioscience.

About Dare Bioscience

DARE stock →

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

DARE vs PTN FAQ

Which is bigger, Dare Bioscience or Palatin Technologies?

Palatin Technologies (PTN) is larger, with a market capitalization of $8.16M compared with $8.01M for Dare Bioscience (DARE).

Which stock has performed better over the past year, DARE or PTN?

DARE returned -75.75% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.

Are Dare Bioscience and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons